Kymera registers Phase 1 crossover trial testing oral formulations of KT-621

Kymera Therapeutics posted one new clinical trial registration this week.

• Kymera registered "A Study to Evaluate Different Oral Formulations of KT-621," a Phase 1 crossover trial in healthy adult participants. The study is a Phase 1, open-label, crossover study to evaluate the relative bioavailability of different oral formulations of KT-621 in healthy adult participants, sponsored by Kymera Therapeutics, Inc.¹ The trial is listed as recruiting, with an estimated enrollment start of October 2026 and an estimated primary completion of April 2027.¹ It plans to enroll 54 participants¹ and is running at one site in the United States, Celerion in Lincoln, Nebraska.¹